Company intelligence / Profile preview
Connext
Seongnam-si, Gyeonggi-do, South Koreaconnext.co.kr ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
CNT201, a recombinant collagenase, completed Phase I dose escalation in Dupuytren's contracture with no dose-limiting toxicities and demonstrated clear therapeutic benefit. Phase II is set to begin Q3'25. CNT101, a recombinant TLR5 agonist, has IND clearance for acute graft-versus-host disease; clinical development ongoing.
- Therapeutic areas
- DermatologyHematologyGastroenterologyOncologyMen's HealthImmunologyRheumatology
- Modalities
- Recombinant proteinProtein (for collagenase and TLR5 agonist)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Connext.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Connext.